APR Apria

Apria Completes Secondary Offering of Common Stock

Apria Completes Secondary Offering of Common Stock

INDIANAPOLIS, June 14, 2021 (GLOBE NEWSWIRE) -- Apria, Inc. (the “Company” or “Apria”) (Nasdaq: APR) announced today the completion of a secondary offering of 5,175,000 shares of Apria common stock by a selling stockholder affiliated with Blackstone at a price to the public of $27.00 per share, including 675,000 shares sold in connection with the full exercise of the option to purchase additional shares granted to the underwriters, resulting in gross proceeds of over $139.7 million.

Apria did not offer any shares of its common stock and did not receive any net proceeds from the sale of common stock by the selling stockholder.  

Citigroup and Goldman Sachs & Co. LLC acted as joint lead book-running managers for the offering. BofA Securities, UBS Investment Bank and J.P. Morgan acted as joint book-running managers for the offering. Piper Sandler, Citizens Capital Markets, Fifth Third Securities, TD Securities, Academy Securities, Blaylock Van, LLC, Penserra Securities LLC and Stern acted as co-managers for the offering.

The offering of these securities was made only by means of a prospectus. A copy of the final prospectus relating to the offering may be obtained from: Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at 1-800-831-9146 or by email at ; Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY, by telephone at 1-212-902-1171, by facsimile at 1-212-902-9316 or by email at l.gs.com; BofA Securities, Attention: Prospectus Department, NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte NC 28255-0001 or by email at ; UBS Securities LLC, Attention: Prospectus Department, 1285 Avenue of the Americas, New York, NY 10019, by telephone at (888) 827-7275 or by emailing ; or J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, by telephone at 1-866-803-9204 or by email at .

A registration statement, including a prospectus, relating to these securities has been filed with the Securities and Exchange Commission (the “SEC”) and has become effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Apria

Apria is a leading provider of integrated home healthcare equipment and related services in the United States, providing home respiratory therapy, obstructive sleep apnea treatment and negative pressure wound therapy. Its approximately 275 locations throughout the continental United States and Hawaii serve nearly 2 million patients each year. All of Apria’s locations are accredited by The Joint Commission.        

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. In some cases, you can identify these forward-looking statements by the use of words such as “outlook,” “believes,” “expects,” “potential,” “continues,” “may,” “will,” “should,” “could,” “seeks,” “predicts,” “intends,” “trends,” “plans,” “estimates,” “anticipates” or the negative version of these words or other comparable words. These forward-looking statements include any statements regarding the offering of Apria common stock. Such forward-looking statements are subject to various risks and uncertainties. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. These factors include but are not limited to those described under “Item 1A. Risk Factors” in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020, as filed with the SEC, as such factors may be updated from time to time in the Company’s periodic filings with the SEC. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in the Company’s filings with the SEC. Investors are urged to consider carefully the disclosure in the Company’s filings with the SEC, which are accessible on the SEC’s website at The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law.

Investor Contacts



Media Contacts





EN
14/06/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Apria

 PRESS RELEASE

Apria Announces Financial Results for Fourth Quarter and Full Year 202...

Apria Announces Financial Results for Fourth Quarter and Full Year 2021 INDIANAPOLIS, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Apria, Inc. (the “Company” or “Apria”) (Nasdaq: APR), a leading provider of integrated home healthcare equipment and related services in the United States, announced today financial results for the fourth quarter and full year ended December 31, 2021. As previously announced, the Company will not be hosting a conference call to discuss its financial results. “We reported solid fourth quarter financial results and 2021 was a good year for Apria. Our team did an excellent...

 PRESS RELEASE

Apria Announces Expiration of Hart-Scott-Rodino Waiting Period

Apria Announces Expiration of Hart-Scott-Rodino Waiting Period INDIANAPOLIS, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Apria, Inc. (the “Company” or “Apria”) (Nasdaq: APR), a leading provider of home medical equipment, supplies and related services in the United States, announced today that the waiting period has expired under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, in connection with its previously announced transaction with Owens & Minor, Inc. The closing of the transaction remains subject to approval by holders of a majority of the Company’s outstanding common sto...

 PRESS RELEASE

Apria Completes Secondary Offering of Common Stock

Apria Completes Secondary Offering of Common Stock INDIANAPOLIS, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Apria, Inc. (the “Company” or “Apria”) (Nasdaq: APR) announced today the completion of a secondary offering of 4,500,000 shares of Apria common stock by a selling stockholder affiliated with Blackstone at a price to the public of $31.50 per share, resulting in gross proceeds of $141.75 million. The selling stockholder has also granted the underwriters an option, exercisable for 30 days from November 10, 2021, to purchase up to an additional 675,000 shares of Class A common stock. Apria did ...

 PRESS RELEASE

Apria Announces Pricing of Secondary Offering of Common Stock

Apria Announces Pricing of Secondary Offering of Common Stock INDIANAPOLIS, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Apria, Inc. (the “Company” or “Apria”) (Nasdaq: APR) announced today the pricing of a previously announced secondary offering of 4,500,000 shares of Apria common stock by a selling stockholder affiliated with Blackstone at a price to the public of $31.50 per share. The selling stockholder has also granted the underwriters a 30-day option to purchase up to 675,000 additional shares of common stock. The offering is expected to close on November 15, 2021, subject to customary closing...

 PRESS RELEASE

Apria Announces Launch of Secondary Offering of Common Stock

Apria Announces Launch of Secondary Offering of Common Stock INDIANAPOLIS, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Apria, Inc. (the “Company” or “Apria”)  (Nasdaq: APR) announced today that a selling stockholder affiliated with Blackstone has commenced a secondary offering of 4,500,000 shares of Apria common stock. In connection with the offering, the selling stockholder intends to grant the underwriters a 30-day option to purchase up to an additional 675,000 shares of common stock. Apria is not offering any shares of its common stock and will not receive any net proceeds from the sale of comm...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch